We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

115 hedge funds and large institutions have $992M invested in Aurinia Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

629% more capital invested

Capital invested by funds: $136M → $992M (+$856M)

550% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 8

127% more call options, than puts

Call options by funds: $89.1M | Put options by funds: $39.3M

60% more funds holding

Funds holding: 72 → 115 (+43)

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

17.96% more ownership

Funds ownership: 27.74% → 45.7% (+18%)

Holders
115
Holders Change
+43
Holders Change %
+59.72%
% of All Funds
2.27%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.12%
New
52
Increased
28
Reduced
19
Closed
8
Calls
$89.1M
Puts
$39.3M
Net Calls
+$49.8M
Net Calls Change
+$49.3M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$63.6M
2
CCM
Consonance Capital Management
New York
+$37.4M
3
HM
HealthCor Management
New York
+$36.7M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$32.9M
5
BBA
Baker Bros. Advisors
New York
+$15.7M

Top Sellers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
-$17.7M
2
O
OrbiMed
New York
-$10.9M
3
Goldman Sachs
Goldman Sachs
New York
-$9.5M
4
Ameriprise
Ameriprise
Minnesota
-$1.96M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
101
Advisory Alpha
Michigan
$39.6K – – –
LTFS
102
Ladenburg Thalmann Financial Services
Florida
$37K – – –
FDCDDQ
103
Federation des caisses Desjardins du Quebec
Quebec, Canada
$28.3K -$7.37K -800 -36%
TCOV
104
Trust Company of Vermont
Vermont
$20K – – –
HCM
105
Highlander Capital Management
New Jersey
$20K +$9.21K +1,000 New
SL
106
Savior LLC
Massachusetts
$16K +$7.38K +801 New
APA
107
American Portfolios Advisors
New York
$15.7K +$7.15K +776 New
SFS
108
Sowell Financial Services
Arkansas
$13K +$5.89K +640 New
HR
109
Howe & Rusling
New York
$12K – – –
Daiwa Securities Group
110
Daiwa Securities Group
Japan
$11K -$415 -45 -8%
WAP
111
Wealthcare Advisory Partners
Pennsylvania
$10K – – –
Carson Wealth (CWM LLC)
112
Carson Wealth (CWM LLC)
Nebraska
$6K – – –
CL
113
CSS LLC
Illinois
$4K +$2.04K +222 New
LWM
114
Liberty Wealth Management
California
$2K – – –
PNC Financial Services Group
115
PNC Financial Services Group
Pennsylvania
$1K +$230 +25 New
PC
116
Polar Capital
United Kingdom
– -$17.7M -3,312,723 Closed
D.E. Shaw & Co
117
D.E. Shaw & Co
New York
– -$1.79M -335,027 Closed
DMK
118
David M. Knott
– -$283K -53,000 Closed
ECM
119
ExodusPoint Capital Management
New York
– -$152K -28,400 Closed
CAM
120
Cresset Asset Management
Illinois
– -$69K -13,000 Closed
CG
121
Cutler Group
California
– -$25.8K -2,800 Closed
PA
122
Parallel Advisors
California
– -$13K -2,500 Closed
CAPTRUST Financial Advisors
123
CAPTRUST Financial Advisors
North Carolina
– -$12K -2,200 Closed
1 2 3 4
5

AUPH Hedge Fund Activity: Q4 2019 in Review

115 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2019, worth a combined $992M — up 629% from $136M a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new AUPH positions and 8 closed out — a net gain of 44 holders — while 28 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $63.6M. The largest seller was Polar Capital, exiting entirely with an estimated $17.7M sold.

  • 115 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2019, up from 72 in Q3 2019.
  • Funds reported $992M of Aurinia Pharmaceuticals stock for Q4 2019, up 629% quarter-over-quarter.
  • 52 funds opened new Aurinia Pharmaceuticals positions in Q4 2019 and 8 closed out, a net change of +44 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q4 2019 was Fidelity Investments, an estimated $63.6M added.
  • The largest Aurinia Pharmaceuticals seller in Q4 2019 was Polar Capital, an estimated $17.7M sold.

Based on aggregated 13F filings for Q4 2019.